Pharma company's RMB30 million patent windfall emphasises need for greater Chinese IP value expertise
China’s desperate need for more IP strategy expertise is an issue that this blog has addressed on several occasions previously. A story IAM heard from a senior IP executive at a Chinese pharmaceutical manufacturer last week drives the point home.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.